Financial Summary (For the fiscal year ended March 31, 2019) [Under Japanese GAAP] (Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)

Code Number: 4559 (URL: http://www.zeria.co.jp/)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039

Scheduled date of ordinary general meeting of shareholders: June 27, 2019

Scheduled date to commence dividend payments: June 28, 2019 Scheduled date to submit the Securities Report: June 27, 2019 Preparation of supplementary documents to the financial results:

Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2018 through March 31, 2019)

(1) Consolidated Financial Results (Percentage figures indicate changes from the previous year.)

Yes

(-)				(ges areas and provi	2 002 3 2 00219
	Net sales		Net sales Operating profit		Ordinary profit		Profit attributable to owners of parent	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2019	61,831	(4.2)	3,737	(22.6)	3,295	(35.2)	3,454	(16.9)
March 31, 2018	64,568	(0.4)	4,830	6.4	5,089	14.7	4,157	17.3

Note: Comprehensive income: For the year ended March 31, 2019: 350 million yen [(96.3)%]For the year ended March 31, 2018: 9,510 million yen [464.1%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ordinary profit to total assets	Operating profit to net sales
Year ended	Yen	Yen	%	%	%
March 31, 2019	69.56	_	5.5	2.9	6.0
March 31, 2018	80.72	_	6.5	4.4	7.5

Reference: Share of profit (loss) of entities accounted for using equity method: For the year ended March 31, 2019: – million yen

For the year ended March 31, 2018: – million yen

(2) Consolidated Financial Position

(-) • • • • • • • • • • • • • • • • • • •									
	Total assets	Net assets	Equity ratio	Net assets per share					
As of	Million yen	Million yen	%	Yen					
March 31, 2019	110,433	59,347	53.6	1,235.09					
March 31, 2018	115,400	65,696	56.8	1,300.88					

Reference: Equity: As of March 31, 2019: 59,185 million yen As of March 31, 2018: 65,532 million yen

(3) Consolidated Cash Flows

	Cash flows from	Cash flows from Cash flows from		Cash and cash equivalents
	operating activities	investing activities	financing activities	at the end of term
Year ended	Million yen	Million yen	Million yen	Million yen
March 31, 2019	5,500	(2,855)	(4,534)	7,920
March 31, 2018	8,821	1,563	(9,628)	10,034

2. Dividends

		Aı	nnual divide	nds	Total	Payout ratio	Dividend rate	
	First quarter	Second quarter	Third quarter	Year-end	Total	dividends paid (Total)	(Consolidated)	for net assets (Consolidated)
Year ended	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
March 31, 2018	-	17.00	_	17.00	34.00	1,723	42.1	2.7
March 31, 2019	-	17.00	_	17.00	34.00	1,666	48.9	2.7
Year ending								
March 31, 2020	-	17.00	_	17.00	34.00		42.9	
(Forecast)								

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2020 (April 1, 2019 through March 31, 2020)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First six months	31,000	1.7	1,800	(13.0)	1,800	(6.0)	1,400	(38.6)	29.22
Full year	65,000	5.1	5,000	33.8	5,000	51.7	3,800	10.0	79.30

* Notes

(1) Significant changes of subsidiaries during the fiscal year ended March 31, 2019 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –)

Exclusion: – (Company name: –)

- (2) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections
 - 1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
 - 2) Changes in accounting policies due to other reasons: None
 - 3) Changes in accounting estimates: None
 - 4) Restatement of prior period financial statements after error corrections: None
- (3) Number of shares issued (common stock)
 - 1) Number of shares issued as of the end of the term (including treasury stock):
 As of March 31, 2019: 53,119,190 shares
 As of March 31, 2018: 53,119,190 shares
 - 2) Number of shares of treasury stock as of the end of the term:
 As of March 31, 2019: 5,199,132 shares
 As of March 31, 2018: 2,743,545 shares
 - 3) Average number of shares during the term:

For the year ended March 31, 2019: 49,655,251 shares For the year ended March 31, 2018: 51,507,358 shares

Reference: Summary of Non-consolidated Financial Results

Non-consolidated Financial Highlights (April 1, 2018 through March 31, 2019)

(1) Non-consolidated Financial Results

(Percentage figures indicate changes from the previous year.)

(1) 1 1011 10110				(comage manes man	oute enu	1500 mom the previo	as jean.
	Net sales		Operating profit		Ordinary profit		Profit	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2019	42,944	(7.7)	1,547	(11.1)	2,637	(6.6)	3,588	27.7
March 31, 2018	46,528	(1.9)	1,740	110.8	2,825	46.2	2,809	20.0

	Basic earnings per share	Diluted earnings per share
Year ended	Yen	Yen
March 31, 2019	72.27	_
March 31, 2018	54.55	_

(2) Non-consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share	
As of	Million yen	Million yen	%	Yen	
March 31, 2019	86,786	45,663	52.6	952.92	
March 31, 2018	88,623	49,523	55.9	983.08	

Reference: Equity: As of March 31, 2019: 45,663 million yen

As of March 31, 2018: 49,523 million yen

* Financial Summary Is Not Required to Be Audited by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.